# US 2013/0252879 A1 · Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252879 A1
- Document ID: US20130252879A1
- Status: Published application
- Kind: A1
- Application number: 13/881,857
- Filed: 2011-10-25
- Published: 2013-09-26
- Earliest claimed: 2010-10-26
- Assignees: Industry-Academic Cooperation Foundation, Yeungnam University
- Inventors: Kyung-Hyun Cho
- Web page: https://patentgrep.com/patent/US20130252879A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 9/1275: Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 14/775: Apolipopeptides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided is a rapamycin formulation using a recombinant high-density lipoprotein including apolipoprotein mutant, the rapamycin formulation in which solubility of rapamycin and medical use, such as aging suppression and arteriosclerosis suppression, are improved by using recombinant high-density lipoprotein including apolipoprotein A-I and its mutant V156K.

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7

A rapamycin formulation comprising rapamycin in an amount of 0.1 to 10 parts by weight based on a total 100 parts by weight of a recombinant high-density lipoprotein, wherein the recombinant high-density lipoprotein includes wild type apolipoprotein A-I or its mutant V156K that is prepared by substituting an amino acid at the location of No. 156 of apolipoprotein (apoA-I) with lysine.

### Claim 8 (depends on 7)

The rapamycin formulation of claim 7, wherein the recombinant high-density lipoprotein comprises any one selected from wild type apolipoprotein A-I or its mutant V156K; phospholipid; cholesterol; and sodium cholate.

### Claim 9 (depends on 7)

The rapamycin formulation of claim 7, wherein the recombinant high-density lipoprotein comprises a mole ratio of 90 to 100 of any one selected from wild type apolipoprotein A-I or its mutant V156K: 1 to 10 of phospholipid: 0.1 to 2.0 of cholesterol: 120 to 180 of sodium cholate.

### Claim 10 (depends on 7)

The rapamycin formulation of claim 7, wherein an amount of the rapamycin is in a range of 0.1 to 20 parts by weight based on a total 100 parts by weight of any one selected from wild type apolipoprotein A-I or its mutant V156K.

### Claim 11 (depends on 7)

The rapamycin formulation of claim 7, wherein the rapamycin formulation prevents aging or improves arteriosclerosis.

### Claim 12

A method of preparing rapamycin formulation, comprising:
preparing any one selected from wild type apolipoprotein A-I or its mutant V156K that is prepared by substituting an amino acid at the location of No. 156 of apolipoprotein (apoA-I) with lysine;
mixing any one selected from wild type apolipoprotein A-I or its mutant V156K with phospholipid, cholesterol, and sodium cholate to prepare recombinant high-density lipoprotein; and
adding rapamycin to the recombinant high-density lipoprotein.
